Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.

Sue Ping Thang, Winnie Wing Chuen Lam, Aaron Kian Ti Tong, Xuexian Yan, Hian Liang Huang and David Chee Eng Ng
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 535;
Sue Ping Thang
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winnie Wing Chuen Lam
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Kian Ti Tong
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuexian Yan
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hian Liang Huang
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Chee Eng Ng
1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 60 no. supplement 1 535

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 21, 2019.

Copyright & Usage 
© 2019

Author Information

  1. Sue Ping Thang1,
  2. Winnie Wing Chuen Lam1,
  3. Aaron Kian Ti Tong1,
  4. Xuexian Yan1,
  5. Hian Liang Huang1 and
  6. David Chee Eng Ng1
  1. 1Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2019 to April 2025

AbstractFullPdf
May 2019200
Jun 20197500
Jul 20193300
Aug 20192200
Sep 20192600
Oct 20195300
Nov 20195200
Dec 20196700
Jan 20205800
Feb 20207400
Mar 202012300
Apr 20204700
May 20204400
Jun 20206500
Jul 20205300
Aug 20207600
Sep 20209100
Oct 20206100
Nov 20205000
Dec 20202400
Jan 20211700
Feb 20212100
Mar 20213600
Apr 20214200
May 20213000
Jun 20213200
Jul 20215300
Aug 20215700
Sep 20213200
Oct 20215500
Nov 202111400
Dec 20215400
Jan 202211400
Feb 20224800
Mar 20225000
Apr 20221700
May 20226600
Jun 20221900
Jul 2022400
Aug 20221100
Sep 2022900
Oct 2022400
Nov 2022200
Dec 2022600
Jan 20231000
Feb 2023600
Mar 20231200
Apr 2023400
May 20231000
Jun 2023700
Jul 20231000
Aug 20231900
Sep 20231200
Oct 20231300
Nov 2023800
Dec 2023700
Jan 20241500
Feb 2024600
Mar 2024400
Apr 2024600
May 2024600
Jun 2024600
Jul 2024600
Aug 20241100
Sep 20242200
Oct 20241200
Nov 20241600
Dec 2024100
Jan 2025400
Feb 2025900
Mar 2025500
Apr 20251200
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.
Sue Ping Thang, Winnie Wing Chuen Lam, Aaron Kian Ti Tong, Xuexian Yan, Hian Liang Huang, David Chee Eng Ng
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 535;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.
Sue Ping Thang, Winnie Wing Chuen Lam, Aaron Kian Ti Tong, Xuexian Yan, Hian Liang Huang, David Chee Eng Ng
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 535;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • Simultaneous PET/MR reveals significant correlation between the intravoxel incoherent motion parameters and standardized uptake values in nasopharyngeal carcinoma patients
  • Accuracy of 18F-fluoroethyltyrosine PET for detecting high grade glioma recurrence: size matters
Show more Oncology: Clinical Therapy and Diagnosis

Prostate Therapy II

  • Treatment of liver metastases of castration resistant prostate cancer with 177Lu-PSMA-617 and SIRT
  • Salivary gland toxicity after PRLT using Lu-177 PSMA in patients with advanced prostate cancer: A single-center systematic investigation
  • 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
Show more Prostate Therapy II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire